Carisma Therapeutics Stock (NASDAQ:CARM)

Forecast Revenue Ownership Financials Chart

Previous Close

$0.21

52W Range

$0.16 - $1.91

50D Avg

$0.38

200D Avg

$0.77

Market Cap

$8.91M

Avg Vol (3M)

$305.05K

Beta

2.79

Div Yield

-

CARM Company Profile

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

46

IPO Date

Feb 06, 2014

Website

CARM Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24	Dec 20
Milestones	$2.00M	-
License Revenue	-	$11.24M

Fiscal year ends in Dec 24 | Currency in USD

CARM Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	$14.92M	$9.83M
Operating Income	-	$-88.73M	$-56.16M
Net Income	$-60.48M	$-86.88M	$-61.23M
EBITDA	-	$-85.89M	$-51.99M
Basic EPS	$-1.46	$-2.59	$-575.42
Diluted EPS	$-1.46	$-2.59	$-575.42

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
HEPA	Hepion Pharmaceuticals, Inc.
ZVSA	ZyVersa Therapeutics, Inc.
CNSP	CNS Pharmaceuticals, Inc.
IMMX	Immix Biopharma, Inc.
ZURA	Zura Bio Limited
PALI	Palisade Bio, Inc.
ENVB	Enveric Biosciences, Inc.